{"id":6735,"date":"2023-02-16T07:00:00","date_gmt":"2023-02-16T07:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2022\/"},"modified":"2023-02-16T07:00:00","modified_gmt":"2023-02-16T07:00:00","slug":"nanexa-publicerar-bokslutskommunike-for-2022","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2022\/","title":{"rendered":"Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2022"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Avtal och riktad emission till Novo Nordisk, l\u00f6sning p\u00e5 patentintr\u00e5ngsprocessen och start av fas 1-studie med NEX-20<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p><strong>V\u00e4sentliga h\u00e4ndelser under fj\u00e4rde kvartalet 2022<\/strong><\/p>\n<ul>\n<li>Nanexa tecknade under kvartalet ett exklusivitets- och utv\u00e4rderingsavtal, ett s\u00e5 kallat Material Transfer and Feasibility Study Agreement, med det ledande globala l\u00e4kemedelsbolaget Novo Nordisk A\/S (\u201dNovo Nordisk\u201d) f\u00f6r utv\u00e4rdering av Nanexas drug delivery-system PharmaShell\u00ae tillsammans med Novo Nordisks produkter inom en viss substansklass. Som en del av utv\u00e4rderingsavtalet erh\u00e5ller Nanexa betalningar om cirka 46,1 MSEK f\u00f6r att ge Novo Nordisk en tidsbegr\u00e4nsad exklusivitet samt f\u00f6r det arbete som utf\u00f6rs under utv\u00e4rderingsperioden. I samband med avtalet genomf\u00f6rdes \u00e4ven en riktad emission till Novo Nordisk som tillf\u00f6rde Nanexa 17,2 MSEK f\u00f6re emissionskostnader och gjorde Novo Nordisk till st\u00f6rsta \u00e4gare med 16,5 procent av bolagets aktier och r\u00f6ster<\/li>\n<li>Nanexa startade enligt plan Fas 1-studien med NEX-20, en l\u00e5ngtidsverkande formulering av lenalidomid f\u00f6r behandling av multipelt myelom. Studien g\u00f6rs med friska frivilliga i syfte att studera den farmakokinetiska profilen, s\u00e4kerhet och tolerabilitet av l\u00e4kemedlet<\/li>\n<li>Nanexa AB och VitriVax, Inc. meddelade gemensamt att de har n\u00e5tt en l\u00f6sning p\u00e5 den patentintr\u00e5ngsprocess som Nanexa AB l\u00e4mnat in mot VitriVax, Inc. i USA:s distriktsdomstol f\u00f6r District of Delaware<\/li>\n<li>Nanexa tecknade ett s\u00e5 kallat Material Transfer and Feasibility Study Agreement med ett l\u00e4kemedelsbolag f\u00f6r utv\u00e4rdering av Nanexas drug delivery-system PharmaShell i en dep\u00e5formulering av ett specifikt l\u00e4kemedel f\u00f6r intravitreal administrering<\/li>\n<li>Under kvartalet uts\u00e5gs en valberedning i Nanexa AB (publ) inf\u00f6r \u00e5rsst\u00e4mman 2023, i enlighet med de principer som beslutades av Nanexas \u00e5rsst\u00e4mma 9 juni 2022, best\u00e5ende av Philip Norin, Hanno Lindroth (utsedd av M\u00e5rten Rooth), Christian \u00d6stberg (utsedd av Anders Johansson) och G\u00f6ran Ando (styrelseordf\u00f6rande, adjungerad).<\/li>\n<\/ul>\n<p><strong>V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng<\/strong><\/p>\n<ul>\n<li>Inga v\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng.<\/li>\n<\/ul>\n<p><strong>Sammanfattning av rapportperioden 1 oktober \u2013 31 december 2022<\/strong><\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 819 (670) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -17 869 (-13 045) kSEK<\/li>\n<li>Resultatet efter skatt uppgick till: -17 932 (-13 087) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,35 (-0,26) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: 35 574 (-14 139) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 81 182 (105 660) kSEK<\/li>\n<\/ul>\n<p><strong>Sammanfattning av rapportperioden 1 januari \u2013 31 december 2022<\/strong><\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 2 860 (2 374) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -57 981 (-35 821) kSEK<\/li>\n<li>Resultatet efter skatt uppgick till: -58 571 (-35 999) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -1,16 (-1,01) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: -24 478 (92 969) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 81 182 (105 660) kSEK<\/li>\n<li>Styrelsen f\u00f6resl\u00e5r att ingen utdelning l\u00e4mnas f\u00f6r r\u00e4kenskaps\u00e5ret 2022.<\/li>\n<\/ul>\n<p><em>Siffror inom parentes avser motsvarande period f\u00f6reg\u00e5ende \u00e5r.<\/em><\/p>\n<p>Rapporten i sin helhet finns tillg\u00e4nglig p\u00e5 bolagets hemsida: https:\/\/nanexa.com\/finansiella-rapporter\/.<\/p>\n<p><strong>Rapportkommentar 16 februari kl 14:00<\/strong><br \/>En lives\u00e4nd kommentar med vd David Westberg h\u00e5lls den 16 februari kl. 14:00 via Infront Direkt Studios och tittarna ges m\u00f6jlighet att st\u00e4lla fr\u00e5gor via chat.<\/p>\n<p><a href=\"https:\/\/eur01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fwww.youtube.com%2Flive%2FNMKq6Hl-7Sw%3Ffeature%3Dshare&amp;data=05|01|dennis.bader%40narva.se|61e29267ece04a82523708db0b71167b|71d2b4ee735e4f73b8ea8254022c0e4d|0|0|638116352559719884|Unknown|TWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D|3000|||&amp;sdata=0CF0GfHKf7VqgLBZxe7rWsgIpvdoUJuiscV4r5ZYHXw%3D&amp;reserved=0\" rel=\"noopener\" target=\"_blank\">Rapportkommentaren kan ses via denna l\u00e4nk<\/a>.<\/p>\n<p>Rapportkommentaren kommer \u00e4ven att l\u00e4ggas upp p\u00e5 Nanexas hemsida i efterhand.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr\/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a><\/p>\n<p>Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr\/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Nanexa \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2023-02-16 08:00 CET.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/0732a8c3-48d2-4736-8530-2be263145170\/nanexa-bokslutskommunike-2022.pdf\" rel=\"noopener\" target=\"_blank\">Nanexa Bokslutskommunike 2022<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Avtal och riktad emission till Novo Nordisk, l\u00f6sning p\u00e5 patentintr\u00e5ngsprocessen och start av fas 1-studie med NEX-20<\/p>\n","protected":false},"template":"","class_list":["post-6735","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim-q4_sv","mfn-news-tag-mfn-report-interim_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2022 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2022\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2022 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Avtal och riktad emission till Novo Nordisk, l\u00f6sning p\u00e5 patentintr\u00e5ngsprocessen och start av fas 1-studie med NEX-20\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-bokslutskommunike-for-2022\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-bokslutskommunike-for-2022\\\/\",\"name\":\"Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2022 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2023-02-16T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-bokslutskommunike-for-2022\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-bokslutskommunike-for-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-bokslutskommunike-for-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2022 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2022\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2022 - Nanexa AB","og_description":"Avtal och riktad emission till Novo Nordisk, l\u00f6sning p\u00e5 patentintr\u00e5ngsprocessen och start av fas 1-studie med NEX-20","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2022\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2022\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2022\/","name":"Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2022 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2023-02-16T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2022\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2022"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=6735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}